

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Cimzia (certolizumab) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorization: 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Cimzia (certolizumab).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: <u>1-866-331-2104</u>]. If you have any questions or concerns, please call <u>1-866-331-2103</u>. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://pithelp.appl.kp.org/MAS/formulary.html**

	1 – Patient Information	
Patient Name:	Kaiser Medical ID#:	Date of Birth:
	2 – Provider Information	
Provider Name:	Specialty:	Provider NPI:
Provider Address:		
Provider Phone #:	Provider Fax #:	
Please check the boxes that apply: □ Initial Request □ Continuation of Therapy R	equest	
	3 – Pharmacy Information	
Pharmacy Name:	Pharmacy NPI:	
Pharmacy Phone #	Pharmacy Fax #:	
	4 – Drug Therapy Requested	
Drug 1: Name/Strength/Formulation:		
Sig:		
Drug 2: Name/Strength/Formulation:		
Sig:		

5- Diagnosis/Clinical Criteria

	5 2.48.100.07 6.11.101.10
1.	Does the member have diagnosis of one of the following? AND ☐ Rheumatoid Arthritis (RA)
	□ Adult Crohn's disease (CD)
	□ Psoriatic arthritis (PsA)
	□ Ankylosing Spondylitis (AS)
	☐ Active Non-radiographic Axial Spondylarthritis (nr-axSpA)
	□ Other:
2.	Was there therapeutic failure on oral methotrexate? AND □ No □ Yes
3.	Was there therapeutic failure to one of the preferred agents? (e.g. Enbrel, Humira) AND \Box No \Box Yes
4.	If this is being used for <u>Active Non-radiographic Axial Spondylarthritis</u> (nr-axSpA): a. Does the patient have objective signs of inflammation? AND □ No □ Yes
	 b. Did the patient have and inadequate response, intolerance, or contraindication to at least TWO non-steroidal anti-inflammatory drugs (NSAIDs)? □ No □ Yes
5.	If this is being used for <u>Ankylosing spondylitis</u> (AS): a. Did the patient try and fail an adequate trial of at least two NSAIDs? OR □ No □ Yes
	b. Is use of NSAIDs is contraindicated in patient?□ No □ Yes
6.	If this is being used for <u>Crohn's Disease</u> (CD): a. Did the patient try and fail a regimen of oral corticosteroids (moderate to severe CD) unless contraindicated? OR □ No □ Yes i. Were they compliant? □ No □ Yes
	 b. Did the patient try and fail intravenous corticosteroids (severe and fulminant CD or failure to respond to oral corticosteroids)? AND □ No □ Yes
	 c. Did the patient try and fail a regimen of azathioprine or mercaptopurine for three consecutive months? AND □ No □ Yes i. Were they compliant? □ No □ Yes

d.	Did the patient try and fail a regimen of parenteral methotre □ No □ Yes	exate for three consecutive months?
	i. Were they compliant?	
	□ No □ Yes	
	s being used for <u>Psoriatic Arthritis</u> (PsA):	
a.	Did the patient try and fail Methotrexate? OR □ No □ Yes	
b.	Does the patient have a contraindication to Methotrexate? (disease, or other contraindication) OR \Box No \Box Yes	(e.g., alcohol abuse, cirrhosis, chronic liver
C.	Will this medication be used in conjunction with Methotrexa \Box No \Box Yes	ate?
. If this i	s being used for <u>Rheumatoid Arthritis</u> (RA):	
a.	Did the patient try and fail Methotrexate? OR □ No □ Yes	
b.	Does the patient have a contraindication to Methotrexate? (disease, or other contraindication) AND □ No □ Yes	(e.g., alcohol abuse, cirrhosis, chronic liver
C.	Did the patient try and fail another DMARD (other than Met penicillamine, cyclophosphamide, cyclosporine, gold salts, h or tacrolimus? □ No □ Yes	•
	6 – Provider Sign-Off	
tional Info	ormation – Please provide any additional information that sh	nould be taken into consideration.
ovider Sigi	he information provided is accurate. Supporting documentation is nature:	Date:

intended for receipt by your facility